Buchumschlag

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases

COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors is limited. In this single-center study, antibody levels of the SARS-CoV-2 spike protein were measured ≥ 2 wee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rotterdam, Jil (VerfasserIn) , Thiaucourt, Margot (VerfasserIn) , Weiß, Christel (VerfasserIn) , Schwaab, Juliana (VerfasserIn) , Reiter, Andreas (VerfasserIn) , Kreil, Sebastian (VerfasserIn) , Steiner, Laurenz (VerfasserIn) , Fenchel, Sebastian (VerfasserIn) , Popp, Henning (VerfasserIn) , Hofmann, Wolf-Karsten (VerfasserIn) , Bonatz, Karin (VerfasserIn) , Gerhards, Catharina (VerfasserIn) , Neumaier, Michael (VerfasserIn) , Klein, Stefan (VerfasserIn) , Rao, Sonika (VerfasserIn) , Jawhar, Mohamad (VerfasserIn) , Saußele, Susanne (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 21 May 2022
In: Annals of hematology
Year: 2022, Jahrgang: 101, Heft: 8, Pages: 1825-1834
ISSN:1432-0584
DOI:10.1007/s00277-022-04866-z
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00277-022-04866-z
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00277-022-04866-z
Volltext
Verfasserangaben:Jil Rotterdam, Margot Thiaucourt, Christel Weiss, Juliana Schwaab, Andreas Reiter, Sebastian Kreil, Laurenz Steiner, Sebastian Fenchel, Henning D. Popp, Wolf-Karsten Hofmann, Karin Bonatz, Catharina Gerhards, Michael Neumaier, Stefan A. Klein, Sonika Rao, Mohamad Jawhar, Susanne Saussele
Beschreibung
Zusammenfassung:COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors is limited. In this single-center study, antibody levels of the SARS-CoV-2 spike protein were measured ≥ 2 weeks after 2nd COVID-19 vaccination with a concentration ≥ 0.8 U/mL considered positive. Between July and October 2021, in a total of 373 patients (median age 64 years, 44% women) with myeloid neoplasms (n = 214, 57%), lymphoid neoplasms (n = 124, n = 33%), and other diseases (n = 35, 10%), vaccination was performed with BNT162b2 (BioNTech), mRNA-1273 (Moderna), ChADOx1 (AstraZeneca), or a combination. A total of 229 patients (61%) were on active therapy within 3 months prior vaccination and 144 patients (39%) were previously treated or treatment naïve. Vaccination-related antibody response was negative in 56/373 patients (15%): in 39/124 patients with lymphoid neoplasms, 13/214 with myeloid neoplasms, and 4/35 with other diseases. Active treatment per se was not correlated with negative response. However, rituximab and BTK inhibitor treatment were correlated significantly with a negative vaccination response, whereas younger age and chronic myeloid leukemia (CML) disease were associated with positive response. In addition, 5 of 6 patients with myeloproliferative neoplasm (MPN) and negative vaccination response were on active treatment with ruxolitinib. In conclusion, a remarkable percentage of patients with hematological diseases had no response after 2nd COVID-19 vaccination. Multivariable analysis revealed important factors associated with response to vaccination. The results may serve as a guide for better protection and surveillance in this vulnerable patient cohort.
Beschreibung:Gesehen am 31.10.2023
Beschreibung:Online Resource
ISSN:1432-0584
DOI:10.1007/s00277-022-04866-z

Ähnliche Einträge